Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-fdas-clinical-trial-approval-for-gfh925-kras-g12c-inhibitor-monotherapy-in-phase-iii-registrational-study-treating-metastatic-colorectal-cancer-302121725.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-potent-anti-tumor-efficacy-of-gfh375-an-oral-kras-g12d-onoff-inhibitor-and-its-potential-in-combination-therapy-with-rafmek-clamp-at-2024-aacr-annual-meeting-302111376.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-broad-spectrum-activity-of-gfh547-an-oral-panras-on-inhibitor-and-its-potential-to-overcome-resistance-against-siip-based-kras-inhibitors-in-late-breaking-research-abstract-of-2024-aacr-annual-m-302111456.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-gfh009-granted-with-fda-fast-track-orphan-drug-designations-for-treating-rr-peripheral-t-cell-lymphomas-and-acute-myeloid-leukemia-302032022.html
https://www.prnewswire.com/news-releases/chinas-first-nda-for-a-kras-g12c-inhibitor-nmpa-accepts-new-drug-application-for-gfh925-and-grants-gfh925-with-priority-review-designation-301996973.html
https://www.prnewswire.com/news-releases/genfleet-starts-phase-ibii-trial-of-gfh009-highly-selective-cdk9-inhibitor-treating-patients-with-relapsedrefractory-peripheral-t-cell-lymphomas-ptcl-301952001.html
https://www.prnewswire.com/news-releases/2023-asco--multi-center-data-for-combination-study-of-genfleets-gfh018-tgf--r1-inhibitor-with-anti-pd-1-antibody-demonstrates-significant-potential-to-enhance-efficacy-of-immune-checkpoint-inhibitors-among-ici-naive-patients-301843043.html
https://www.prnewswire.com/news-releases/genfleet-therapeutics-to-present-phase-i-data-for-gfh312-at-2023-american-society-for-clinical-pharmacology--therapeutics-meeting-301765243.html